Written by: the Medetone Medical Team
Medically reviewed by: Dr Abdullah
Reading time: 6 minutes · Guidance verified: October 2026
If you are searching how to use Ozempic for weight loss, you deserve a straight answer rather than a dose chart. The honest one is this: Ozempic is licensed for type 2 diabetes, not for weight management, and a different semaglutide product carries the weight-management licence. That distinction changes what safe use actually looks like. This guide explains the licensing position, what off-label use means in practice, and how to approach treatment properly. It is informational and does not replace advice from your doctor.
The essentials
Ozempic is licensed for: type 2 diabetes
Licensed for weight management: a separate, higher-dose semaglutide product
Using it for weight loss is off-label and requires individual medical assessment
Prescription-only. Never self-source or self-dose
Supervision matters more than the schedule itself
The direct answer
Ozempic contains semaglutide and is authorised for the treatment of type 2 diabetes. That is the indication it was developed, trialled and licensed for, and it is what the official product information from the European Medicines Agency and AEMPS covers.
Weight loss happens as part of how semaglutide works, because reduced appetite is one of its mechanisms. But a medicine producing an effect is not the same as being licensed to treat it.
For weight management specifically, a different semaglutide product is licensed, marketed as Wegovy, at higher doses with its own dedicated trial programme behind it. Same molecule, different doses, different indication, different evidence base. Our guide comparing Wegovy and Ozempic sets out exactly how they differ.
You may see claims that Ozempic is approved in Spain for weight management in overweight adults. That is incorrect, and the official product information is the authoritative source rather than any clinic or blog.
What off-label actually means
Prescribing a licensed medicine for an indication it is not authorised for is called off-label use. It is not illegal, and doctors do it in many areas of medicine where the clinical judgement supports it.
What it does mean is that the decision sits entirely with the prescriber, assessed individually. There is no standard protocol, no licensed dose schedule for that purpose, and the clinician carries responsibility for justifying it.
Which is precisely why the answer to how to use Ozempic for weight loss cannot be a chart you follow from an article. It is a decision made with a clinician who knows your history.
Why the distinction matters practically
Three concrete reasons, beyond the regulatory point.
Dosing differs. The weight-management product uses a higher dose range than the diabetes product. Using the diabetes product for weight loss means working outside the dose range the weight-management evidence was built on.
The evidence differs. Trials in people with type 2 diabetes reported average weight loss of around 4 to 6 kg. Dedicated weight-management trials at higher doses report considerably larger figures. If weight loss is your goal, the evidence that applies is the weight-management evidence.
Supply differs. Demand for off-label use has contributed to shortages affecting people who need the medicine for diabetes. Using the licensed weight-management product avoids that problem entirely.
What safe use actually involves
Whatever is prescribed, four things define proper use.
A full clinical assessment first. Your medical history, current medicines, BMI and any weight-related conditions. A prescriber should be willing to tell you treatment is not appropriate if it is not.
A prescription from a registered source. Never buy semaglutide without one. Counterfeit pens are a documented and ongoing problem, there is no guarantee of correct storage or cold chain, and nobody is monitoring your dose or side effects.
Gradual dose escalation. Every GLP-1 medicine starts low and increases in steps over weeks. The starting dose is not therapeutic; it exists purely to let your body adjust. Rushing this is the single most common cause of poor tolerance, and nausea is far more likely when the schedule is compressed.
Ongoing review. Dose adjustment, side effect management, and periodic reassessment of whether treatment is still right. A service that posts a pen and disappears is not providing supervision.
What to expect
Appetite changes typically appear within the first weeks, usually before any meaningful change on the scale. Many people describe reduced food noise, meaning less constant mental preoccupation with eating, as the first noticeable effect.
Weight change accumulates over months rather than weeks, with maximum effect generally seen somewhere between four and six months of continuous treatment.
Nausea is the most common side effect, most pronounced when starting or increasing the dose, and usually improving as the body adjusts. Diarrhoea, constipation and abdominal pain are also reported.
Two things protect your results. Adequate protein and resistance training, because a meaningful proportion of weight lost on any GLP-1 medicine comes from lean muscle rather than fat, as our protein guide explains. And realistic expectations about stopping, since weight regain is common once treatment ends, covered in our guide on stopping weight-loss medication.
Getting treatment properly
If weight management is your goal, the useful step is an assessment rather than choosing a product in advance.
Prescription weight-management treatment is generally considered for adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure, type 2 diabetes or sleep apnoea. Whether it suits you depends on your full picture.
At Medetone, eligible patients can complete a clinical assessment to establish whether a weight-management treatment is appropriate and which licensed option fits. You can read about Wegovy and Mounjaro, or see all weight-loss treatments. Patients in the UK can access care through Medetone UK or our partner service Rightangled, and in the United States through Medetone US.
A clinician reviews your case, dispensing is through a registered pharmacy with proper cold-chain handling, and support continues throughout treatment rather than ending at delivery.
When to seek medical advice
Contact a doctor promptly for severe abdominal pain that does not settle, nausea or vomiting preventing you from eating or drinking, symptoms of low blood sugar such as sweating, trembling or confusion, worsening injection site reactions, or sudden changes in vision.
Frequently asked questions
Can Ozempic be used for weight loss?
It is licensed for type 2 diabetes. Use for weight loss is off-label and must be assessed individually by a prescriber.
What should I use instead?
A licensed weight-management product. Which one suits you is a clinical decision based on your history.
Do I need a prescription?
Yes, always. Semaglutide is prescription-only, and unverified sources carry real risk of counterfeit or poorly stored product.
How long until I see results?
Appetite changes within weeks; meaningful weight change over months, with maximum effect typically at four to six months.
Will I regain the weight?
Commonly, yes, if treatment stops without the habits built alongside it. These are managed as long-term treatments with review.
In summary
How to use Ozempic for weight loss has a clearer answer than most articles give: Ozempic is licensed for type 2 diabetes, and a separate semaglutide product carries the weight-management licence at higher doses with its own evidence base. Using the diabetes product for weight loss is off-label, has no licensed schedule, and must be assessed individually. Whatever is prescribed, safe use means a proper assessment, a registered source, gradual dose escalation and ongoing review. If weight is your concern, an assessment is the right starting point.
Medical information: this article is for information only and does not replace diagnosis, prescription or medical advice. Ozempic is a prescription-only medicine. Treatment is subject to consultation, eligibility and clinical approval. Individual results vary.
References (Spanish and EU official sources):
AEMPS, Agencia Española de Medicamentos y Productos Sanitarios: https://www.aemps.gob.es
CIMA, Centro de Información de Medicamentos (Spain): https://cima.aemps.es
European Medicines Agency, Ozempic: https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic
European Medicines Agency, Wegovy: https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
Ministerio de Sanidad (Spain): https://www.sanidad.gob.es
AIFA, Agenzia Italiana del Farmaco: https://www.aifa.gov.it
ANSM (France): https://ansm.sante.fr
BfArM (Germany): https://www.bfarm.de
